| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c55550b6645e69d856e70fbc3738c7d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2015-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc22953bf6555cd5c31b9de41f601ce0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd2a7818c4b082b2475496aeeb8991de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc48d4f47aa0b163d1acb8873d5aed34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb94f41e2244eeec22256ee8f6f39057
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6005cea324fee5f37d9a425899779d6d |
| publicationDate |
2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2015212733-B2 |
| titleOfInvention |
Small molecule drug conjugates |
| abstract |
A targeted therapeutic agent comprising a compound of formula (I): B–L–D, wherein: B is a low molecular weight binding moiety for Carbonic Anhydrase IX (CAIX); D is a drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The drug moiety is suitably a cytotoxic agent for targeted delivery to cancer cells expressing CAIX. The binding moiety B suitably comprises a sulfonamidothiadiazole moiety. The binding moiety B may comprise one, two or more groups capable of binding to CAIX. The linker group suitably comprises a disulfide bond and/or a triazole group and/or a cleavable peptide group. |
| priorityDate |
2014-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |